Melt Pharmaceuticals Revolutionizes Sedation with $24M Series B

Nashville's Melt Pharmaceuticals secures $24 million in Series B funding to propel the development of MELT-300, a game-changing sedation tablet. Led by CEO Dr. Larry Dillaha, Melt aims to transform procedural sedation with a needle- and opioid-free alternative for medical procedures. The MELT-300 Phase 3 program is underway, with promising results expected by the end of 2024. Melt's innovative approach has garnered support from new and existing investors, highlighting the potential impact of their non-IV, non-opioid therapeutics. With a focus on regulatory approval through the FDA's 505(b)(2) pathway, Melt Pharmaceuticals is poised to revolutionize sedation practices in healthcare settings worldwide.